Novel mechanisms of drug resistance in leukemia

Leukemia

Volumn 14, Issue 3, 2000, Pages 467-473

  Ross, D D ^a,b,c  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

Drug resistance; Leukemia; P glycoprotein

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PROTEIN; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; CONFERENCE PAPER; DRUG EFFICACY; DRUG TRANSPORT; HUMAN; LEUKEMIA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0034009217     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401694     Document Type: Conference Paper

References (80)

1. Murren JR, DeVita VT. Another look at multidrug resistance. Principles Practice Oncol Updates 1995; 9: 1-12.
2. Fisher GA, Sikic BI (eds). Drug resistance in clinical oncology and hematology. Hematol Oncol Clin N Am 1995; 9: 239-382.
3. Leith CP, Kopecky KJ, Godwin JE, McConnell T, Slovak M, Chen IM, Head DR, Appelbaurn F, Willman CL. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323-3329.
4. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelhaum FR, Willman CL. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood 1999; 94: 1086-1099.
5. Samdani A, Vijapurkar U, Grimm MA, Spier CS, Grogan TM, Glinsmann-Gibson BJ, List AF. Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leukemia Res 1996; 20: 175-180.
6. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995; 85: 2147-2153.
7. Wood P, Burgess R, MacGregor A, Yin JA. P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994; 87: 509-514.
8. Lamy T, Goasguen JE, Mordelet E, Grulois I, Dauriac C, Drenou B, Chaperon J, Fauchet R, le Prise PY. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 1994; 8: 1879-1883.
9. Del Poeta G, Venditti A, Aronica G, Stasi R, Cox MC, Buccisano F, Bruno A, Tamburini A, Suppo G, Simone MD, Epiceno AM, Del Moro B, Masi M, Papa G, Amadori S. P-glycoprotein expression in de novo acute myeloid leukemia. Leuk Lymphoma 1997; 27: 257-274.
10. Senent L, Jarque I, Martin G, Sempere A, Gonzalez-Garcia Y, Gomis F, Perez-Srvent M, De La Rubia J, Sanz MA. P-glycoprotein expression and prognostic value in acute myeloid leukemia. Haematologica 1998; 83: 783-787.
11. Zochbauer S, Gsur A, Brunner R, Kyrle PA, Lechner K, Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994; 8: 974-977.
12. Sievers EL, Smith FO, Woods WG, Lee JW, Bleyer WA, Willman CL, Bernstein ID. Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected hy monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Children's Cancer Group. Leukemia 1995; 9: 2042-2048.
13. Ivy SP, Olshefski RS, Taylor BJ, Patel KM, Reaman G. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a Children's Cancer Group study. Blood 1996; 88: 309-318.
14. Dhooge C, De Moerloose B, Laureys G, Kint J, Ferster A, De Bacquer D, Philippe J, Beniot Y. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukemia: results of a 6-year prospective study. Br J Haematol 1999; 105: 676-683.
15. Wattel E, Lepelley P, Merlat A, Sartiaux C, Bauters F, Jouet JP, Fenaux P. Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: absence of correlation with response to treatment. Leukemia 1995; 9: 1870-1874.
16. Nussler V, Pelka-Fleischer R, Zwierzina H, Nerl C, Beckert B, Gieseler F, Diem H, Ledderose G, Gullis E, Sauer H, Wilmanns W. P-glycoprotein expression in patients with acute leukemia-clinical relevance. Leukemia 1996; 10 (Suppl. 3): S23-S31.
17. den Boer ML, Pieters R, Kazemier KM, Rottier MM, Zwaan CM, Kaspers GJ, Janka-Schaub G, Henze G, Creutzig U, Scheper RJ, Veerman AJ. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression and drug resistance in childhood leukemia. Blood 1998; 91: 2092-2098.
18. Kanerva J, Tiirikainen M, Makipernaa A, Riikonen P, Mottonen M, Salmi TT, Krusius T, Saarinen-Pihkala UM. Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL. Pediatr Hematol Oncol 1998; 15: 11-21.
19. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP. Multidrug resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 44-50.
20. Wilson WH, Bates SE, Fojo A, Bryant, G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Hearth J et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995; 13: 1995-2004.
21. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futcher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652-1660.
22. List AF, Kopecky KJ, Willman CL, Spier C, Dorr R, Appelbaum F, Hynes H. Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group study. Blood 1998; 92 (Suppl. 1): 312a.
23. Pallis M, Zhu YM, Russell NH. BclXL is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia 1997; 11: 945-949.
24. Bhalla K, Hindenberg A, Taub RN, Grant S. Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res 1985; 45: 3657-3662.
25. Gervasoni JE Jr, Taub RN, Rosado M, Krishna S, Stewart VJ, Knowles DM, Bhalla K, Ross DD, Baker MA, Lutsky J, Hindenberg AA. Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells. Cancer Chemother Pharmacol 1991; 28: 93-101.
26. Marquardt D, McCrone S, Center MS. Mechanisms of multidrug resistance in HL-60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 1990; 50: 1426-1430.
27. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1654.
28. Lautier D, Canitrot Y, Deeley RG, Cole SPC. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 1996; 52: 967-977.
29. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB. Expression ofthe multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia 1994; 8: 2163-2168.
30. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995; 85: 186-193.
31. Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995; 9: 1661-1666.
32. Filipits M, Suchomel RW, Zochbauer S, Brunner R, Lechner K, Pirker R. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin Cancer Res 1997; 3: 1419-1425.
33. Filipits M, Stranzl T, Pohl G, Suchomel RW, Zochbauer S, Brunner R, Lechner K, Pirker R. MRP expression in acute myeloid leukemia. An update. Adv Exp Med Biol 1999; 47: 141-150.
34. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Baak JP, Eekman CA, Kuiper CM, Feller N, van Heijningen TH, Klumper E, Pieters et al. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1995; 1: 81-93.
35. Legrand O, Simonin C, Beauchamp-Nicoud A, Zittoun R, Marie JP. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in acute myeloid leukemia. Blood 1999; 94: 1046-1056.
36. Kuss BJ, Deeley RG, Cole SP, Willman CL, Kopecky KJ, Wolman SR, Eyre HJ, Lane SA, Nancarrow JK, Whitmore SA, Callen DF. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet 1994; 343: 1531-1534.
37. Allikmets R, Gerrard B, Hutchinson A, Dean M. Characterization of the human ABC superfamily: Isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Gent 1996; 5: 1649-1655.
38. Buchler M, Konig J, Brom M, Kartenbeck J, Spring H, Horie T, Keppler D. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 1996; 271: 15091-15098.
39. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997; 57: 3537-3547.
40. Belinsky MG, Bain LJ, Balsara BB, Testa JR, Kruh GD. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J Natl Cancer Inst 1998; 90: 1735-1741.
41. Lee K, Belinsky MG, Bell DW, Testa JR, Kruh GD. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. Cancer Res 1998; 58: 2741-2747.
42. Belinsky M, Kruh G. MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver. Br J Cancer 1999; 80: 1342-1349.
43. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999; 55: 929-937.
44. Koike K, Kwabe T, Tanaka T, Toh S, Uchiumi T, Wada M, Akiyama S, Ono M, Kuwano M. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997; 57: 5475-5479.
45. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999: 59: 2532-2535.
46. Zeng H, Bain LJ, Belinsky MG, Kruh GD. Expression of MRP-3 in HEK293 cells confers resistance to anticancer agents. Cancer Res (in press).
47. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F, Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999; 96: 694-699.
48. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen THM, van Kalken CK, Slovak ML, de Vries EGE, van der Valk P, Meijer, CJLM, Pinedo HM. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1475-1479.
49. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pineco HM, Meijer CJLM, Clevers HC, Scheper RJ. The drug resistance-related protein LRP is the human major vault protein. Nature Med 1995; 1: 578-582.
50. Chugani DC, Rome LH, Kedersha NL. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 1993; 106: 23-29.
51. List AF, Spier CS, Crogan TM, Johnson C, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464-2469.
52. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jager U, Geissler K, Lechner K, Pirker R. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998; 91: 1508-1513.
53. Izquierdo MA, van der Zee A, Vermoken J, van der Valk P, Belien JAM, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJLM, de Vries EGE, Scheper RJ. Expression of the new drug resistance-associated marker LRP in ovarian carcinoma predicts poor response to chemotherapy and shorter survival. J Natl Cancer Inst 1995; 87: 1230-1237.
54. Raaijmakers HG, Izquierdo MA, Lokhorst HM, de Leeuw C, Belien JA, Bloem AC, Dekker AW, Scheper RJ, Sonneveld P. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998; 91: 1029-1036.
55. Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani G, Scheper RJ, Baccarani M. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol 1999; 104: 328-335.
56. Lepelley P, Poulain S, Grardel N, Preudhomme C, Cosson A, Fenaux P. Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes. Leuk Lymphoma 1998; 29: 547-551.
57. Leith CP, Chen I-M, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/Efflux+ and MDR1+/Efflux-cases. Blood 1995; 86: 2329-2342.
58. Ross DD, Doyle LA, Schiffer CA, Lee EJ, Grant CE, Cole SPC, Deeley RG, Yang W, Tong Y. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Leukemia 1996; 10: 48-55.
59. Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ, Trent JM. Different mechanisms of deceased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF-7 human breast cancer cell line. Br J Cancer 1991; 63: 923-929.
60. Futcher BW, Abbaszadegan MR, Domann F, Dalton WS. Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem Pharm 1994; 47: 1601-1606.
61. Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C, Cowan KH. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr 1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 1992; 52: 6175-6181.
62. Yang C-HJ, Cowan K, Schneider E. Reselection ot a mitoxantrone-resistant breast carcinoma cell line with mitoxantrone results in a parallel increase in cross-resistance to camptothecin analogues. Proc Amer Assoc Cancer Res 1996; 37: 308 (Abstr.).
63. Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T, Greenberger LM. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 1998; 58: 5850-5858.
64. Dietel M, Arps H, Lage H, Niendorf A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 1990; 50: 6100-6106.
65. Chen Y-N, Mickley LA, Schwartz AM, Acton EM, Hwang J, Fojo AT. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 1990; 265: 10073-10080.
66. Doyle LA, Ross DD, Sridhara R, Fojo AT, Kaufmann SH, Lee EJ, Schiffer CA. Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells. Br J Cancer 1995; 71: 52-58.
67. Lee JS, Scala S, Matsumoto Y, Dickstein B, Robey R, Zhan Z, Altenberg G, Bates SE. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem 1997; 65: 513-526.
68. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992; 257: 967-971.
69. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Cao Y, Rishi AK, Ross DD. A novel multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665-15670.
70. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999; 59: 8-13.
71. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998; 58: 5337-5339.
72. Griffith J, Sansom C. The Transporter Fact Book. Academic Press, Harcourt Brace & Company: San Diego, 1998, pp 115-120.
73. Dreesen TD, Johnson DH, Henikoff S. The brown protein of Drosophila melanogaster is similar to the white protein and to components of active transport complexes. Mol Cell Biol 1988; 8: 5206-5215.
74. Tearle RG, Belotte JM, McKeown M, Baker BS, Howells AJ. Cloning and characterization of the scarlet gene of Drosophila melanogaster. Genetics 1989; 122: 595-606.
75. Rabindran SK, He H, Singh M, Ross DD, Doyle LA, Yang W, Bates SE, Greenberger LM. Fumitremorgin C reverses a novel multidrug resistance mechanism in mitoxantrone-selected cells. Proc Amer Assoc Cancer Res 1999; 40: 315 (abstr).
76. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ann Rev Pharmacol Toxicol 1999; 39: 361-398.
77. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SPC, Doyle LA. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999; 91: 429-433.
78. Ma J, Maliepaard M, Nooter K, Loos WJ, Kolker HI, Verweij J, Stoter G, Schellens JH. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer 1998; 77: 1645-1652.
79. Maliepaard M, VanGastelen MA, DeJong LA, Pluim D, van Waardenburg RCAM, Ruevekamp-Helmers MC, Floot BGJ, Schellens JHM. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59: 4559-4563.
80. Ross DD, Karp J, Yang W, Gao Y, Abruzzo LV, Doyle LA. Expression of breast cancer resistance protein (BCRP) in blast cells from patients with acute myeloid leukemia (AML). Blood 1998; 92: 386a.